Deals23 Jan 2025, 07:24 pm
Shilpa Medicare's Subsidiary Receives CEP from EDQM for Teriflunomide API
AI Summary
Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited, has received a certificate of suitability (CEP) from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for the Active Pharmaceutical Ingredient (API), Teriflunomide. Teriflunomide is a disease-modifying agent used for treating multiple sclerosis (MS) and has demonstrated clinical efficacy and safety in various phase 111 clinical trials. It is an attractive treatment option due to its oral administration. The CEP signifies Shilpa's commitment to develop, manufacture, and supply quality products of global standards.
Key Highlights
- Shilpa Medicare's subsidiary, Shilpa Pharma Lifesciences Limited, received a CEP from EDQM for Teriflunomide API
- Teriflunomide is a novel disease-modifying agent for treating multiple sclerosis
- Teriflunomide has shown clinical efficacy and safety in large-scale clinical trials
- Oral administration of Teriflunomide makes it an attractive treatment option
- CEP from EDQM highlights Shilpa's commitment to develop, manufacture, and supply quality products of global standards